Mankind Pharma Poised to Acquire Bharat Serums, Awaiting Binding Bids

Mankind Pharma has emerged as the leading contender to acquire Bharat Vaccines and Serums from Advent International, with a potential deal valued between $1.7 billion and $2 billion, according to insider sources.

Despite its share price falling from a peak of ₹2,490 in April 2024, the company had previously surged from a 52-week low of ₹1,661.05 in July 2023.

Armed with substantial financial resources, Mankind Pharma is expected to bid over $2 billion for Bharat Serums. Official bids are anticipated by mid-month. This acquisition would significantly enhance Mankind Pharma's domestic market presence, particularly in women's healthcare, assisted reproductive treatments, critical care, and emergency medicine, areas where Bharat Serums is already a leader.

Competitive Landscape

Mankind Pharma, headquartered in Delhi, is well-prepared to execute this acquisition without jeopardizing its financial stability. The deal would bolster its product offerings in both acute and therapeutic sectors.

However, Mankind faces competition from two private equity consortiums. Warburg Pincus has partnered with Abu Dhabi’s Mubadala, and the Abu Dhabi Investment Authority is bidding alongside a Swiss private equity firm. The outcome will hinge on the depth of the private equity firms' financial commitments, their valuation assessments, and projected investment returns.

Requests for comments from Mankind Pharma went unanswered. Similarly, Warburg Pincus and Mubadala did not respond, and the Abu Dhabi Investment Authority declined to comment.

Background on Acquisition

Advent International acquired Bharat Serums in 2019 through two transactions worth approximately $500 million. The firm is now seeking a full exit, aiming for returns exceeding three times its initial investment.